Overcoming market access hurdles will be a challenge for a newly approved drug for major depressive disorder, Auvelity. But, a favorable efficacy and adverse event profile will likely help to facilitate patient access.
Auvelity, Newly Approved Drug For Major Depressive Disorder, To Face Payer Pricing And Reimbursement Challenges
